Allergy Therapeutics plc has disclosed a public dealing disclosure by Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. The disclosure includes key information such as the name of the exempt principal trader, the name of the offeror/offeree (Allergy Therapeutics plc), and the date of dealing undertaken (14 Sep 2023).

The disclosure provides details of the dealings by the exempt principal trader, including purchases and sales of the class of relevant security (0.1p ordinary shares). The table shows that the exempt principal trader purchased 136,414 securities at a highest price per unit of 0.028 and a lowest price per unit of 0.026. They also made sales of 50,000 securities at a price per unit of 0.027.

No cash-settled derivative transactions or stock-settled derivative transactions (including options) are disclosed in the form.

The disclosure also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing.

The contact information for the disclosure is provided, including the name of Lauren Riley and the telephone number 020 7886 2963.

It is important to note that this summary is based solely on the information provided in the news and does not include any additional context or analysis.